Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition

Mutations in the adenomatous polyposis coli (APC) gene are a defining feature of colorectal cancer (CRC) and impose metabolic and stress adaptation requirements that may create exploitable vulnerabilities. Prolyl hydroxylase domain (PHD) inhibitors have been explored as therapeutic agents in CRC; however, their mechanisms of action and off-target effects remain elusive. Serendipitously, we found…

Recent research has revealed a potential new approach to treating colorectal cancer (CRC) in patients with APC mutations. Scientists have discovered that Molidustat, a drug that inhibits Prolyl hydroxylase domain (PHD)2, can induce cell death in human APC-mutant colorectal cancer cells. This finding suggests that Molidustat may exploit a metabolic and stress vulnerability present in these cells.

Further investigation into the mechanisms behind Molidustat's effects led to the identification of glutathione S-transferase P1 (GSTP1) as an off-target of the drug. The researchers demonstrated that Molidustat directly inhibits the enzymatic activity of GSTP1. Importantly, they found that the combined loss of both PHD2 and GSTP1 led to synergistic changes in the cell's proteome, which are associated with suppressed cell cycle progression and apoptotic signaling.

To confirm their findings, the researchers used mouse organoids, which are miniature versions of human tissue grown in the lab. They observed that APC-mutant mouse organoids were selectively sensitive to Molidustat, and this sensitivity was not seen when the drug was used alone. These results suggest that the anti-tumor activity of Molidustat may be due to a synthetic lethal interaction between GSTP1 and PHD2 in APC-mutant CRCs.

In summary, this study highlights a novel therapeutic target in colorectal cancer by identifying the functional relationship between GSTP1 and PHD2. The discovery of Molidustat's off-target effect on GSTP1 in APC-mutant cells offers a promising avenue for developing targeted anti-cancer therapies.

Rewritten by urgent.news; may contain errors — check the original.

Source: elifesciences.org

Read the original at elifesciences.org →

Report a problem with this story

More in Health & Medicine

Dengue gallops on

A total of 107,829 dengue cases have been reported across Sri Lanka so far this year, with 81 deaths attributed to the disease, the National Dengue Control Unit (NDCU) said.

More from Tuesday 10 November →